Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Western blot [1]
- ELISA [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- H00002118-M01 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#H00002118-M01, RRID:AB_2100986
- Product name
- Mouse Monoclonal Pea3 Antibody
- Antibody type
- Monoclonal
- Description
- IgG purified. ETV4 - ets variant gene 4 (E1A enhancer binding protein, E1AF)
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Vial size
- 0.1 mg
- Storage
- Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
Submitted references Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways.
Overexpression of ETV4 is associated with poor prognosis in prostate cancer: involvement of uPA/uPAR and MMPs.
Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts.
Overexpression of ETV4 is oncogenic in prostate cells through promotion of both cell proliferation and epithelial to mesenchymal transition.
A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer.
Van den Eynden J, Umapathy G, Ashouri A, Cervantes-Madrid D, Szydzik J, Ruuth K, Koster J, Larsson E, Guan J, Palmer RH, Hallberg B
Science signaling 2018 Nov 20;11(557)
Science signaling 2018 Nov 20;11(557)
Overexpression of ETV4 is associated with poor prognosis in prostate cancer: involvement of uPA/uPAR and MMPs.
Qi M, Liu Z, Shen C, Wang L, Zeng J, Wang C, Li C, Fu W, Sun Y, Han B
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2015 May;36(5):3565-72
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2015 May;36(5):3565-72
Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts.
Mesquita D, Barros-Silva JD, Santos J, Skotheim RI, Lothe RA, Paulo P, Teixeira MR
Oncotarget 2015 Mar 10;6(7):5217-36
Oncotarget 2015 Mar 10;6(7):5217-36
Overexpression of ETV4 is oncogenic in prostate cells through promotion of both cell proliferation and epithelial to mesenchymal transition.
Pellecchia A, Pescucci C, De Lorenzo E, Luceri C, Passaro N, Sica M, Notaro R, De Angioletti M
Oncogenesis 2012 Jul 16;1:e20
Oncogenesis 2012 Jul 16;1:e20
A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer.
Han B, Mehra R, Dhanasekaran SM, Yu J, Menon A, Lonigro RJ, Wang X, Gong Y, Wang L, Shankar S, Laxman B, Shah RB, Varambally S, Palanisamy N, Tomlins SA, Kumar-Sinha C, Chinnaiyan AM
Cancer research 2008 Sep 15;68(18):7629-37
Cancer research 2008 Sep 15;68(18):7629-37
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: Pea3 Antibody (3G9-1B9) [H00002118-M01] - Analysis of ETV4 expression in transfected 293T cell line by ETV4 monoclonal antibody (M01), clone 3G9-1B9.Lane 1: ETV4 transfected lysate(54 KDa).Lane 2: Non-transfected lysate.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Sandwich ELISA: Pea3 Antibody (3G9-1B9) [H00002118-M01] - Detection limit for recombinant GST tagged ETV4 is 0.1 ng/ml as a capture antibody.
